Ruvandhi Nathavitharana, M.B.,B.S.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Tuberculosis | 23 | 2022 | 1912 | 4.400 |
Why?
|
Tuberculosis, Pulmonary | 13 | 2022 | 810 | 3.200 |
Why?
|
Mycobacterium tuberculosis | 18 | 2022 | 1832 | 2.740 |
Why?
|
Tuberculosis, Multidrug-Resistant | 15 | 2021 | 912 | 2.530 |
Why?
|
Latent Tuberculosis | 4 | 2022 | 225 | 1.580 |
Why?
|
Disinfection | 3 | 2020 | 191 | 1.500 |
Why?
|
Antibiotics, Antitubercular | 3 | 2021 | 104 | 0.980 |
Why?
|
Diagnostic Tests, Routine | 3 | 2019 | 783 | 0.940 |
Why?
|
Antitubercular Agents | 10 | 2021 | 1320 | 0.940 |
Why?
|
Air Microbiology | 2 | 2020 | 87 | 0.880 |
Why?
|
Sputum | 7 | 2022 | 476 | 0.800 |
Why?
|
Rifampin | 6 | 2021 | 315 | 0.750 |
Why?
|
Contact Tracing | 1 | 2022 | 273 | 0.690 |
Why?
|
Knowledge | 1 | 2020 | 181 | 0.650 |
Why?
|
Measles | 2 | 2020 | 168 | 0.640 |
Why?
|
Occupational Diseases | 2 | 2017 | 1471 | 0.630 |
Why?
|
Nucleic Acid Amplification Techniques | 3 | 2021 | 323 | 0.630 |
Why?
|
Infection Control | 3 | 2020 | 966 | 0.600 |
Why?
|
Consumer Advocacy | 1 | 2017 | 81 | 0.560 |
Why?
|
Biological Assay | 1 | 2019 | 652 | 0.550 |
Why?
|
Microbial Sensitivity Tests | 4 | 2021 | 1877 | 0.540 |
Why?
|
Sparganosis | 1 | 2015 | 5 | 0.540 |
Why?
|
Spirometra | 1 | 2015 | 5 | 0.540 |
Why?
|
Diffusion of Innovation | 1 | 2020 | 725 | 0.510 |
Why?
|
Tick-Borne Diseases | 1 | 2015 | 34 | 0.500 |
Why?
|
Triage | 2 | 2022 | 976 | 0.460 |
Why?
|
Drug Resistance, Multiple, Bacterial | 1 | 2017 | 567 | 0.420 |
Why?
|
South Africa | 3 | 2022 | 1731 | 0.420 |
Why?
|
Attitude to Health | 1 | 2021 | 2052 | 0.420 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3133 | 0.410 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3240 | 0.410 |
Why?
|
Breast Diseases | 1 | 2015 | 443 | 0.410 |
Why?
|
Nurses | 1 | 2021 | 2461 | 0.400 |
Why?
|
Sensitivity and Specificity | 9 | 2022 | 14722 | 0.400 |
Why?
|
Cross Infection | 2 | 2017 | 1416 | 0.380 |
Why?
|
Drug Resistance, Bacterial | 3 | 2021 | 1035 | 0.370 |
Why?
|
Tuberculin Test | 2 | 2022 | 214 | 0.370 |
Why?
|
Hemorrhagic Fever, Ebola | 1 | 2015 | 428 | 0.360 |
Why?
|
Pandemics | 2 | 2020 | 8388 | 0.360 |
Why?
|
Inpatients | 1 | 2018 | 2518 | 0.280 |
Why?
|
Health Personnel | 2 | 2017 | 3218 | 0.280 |
Why?
|
Sunlight | 1 | 2007 | 325 | 0.270 |
Why?
|
Disease Outbreaks | 1 | 2015 | 1772 | 0.270 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 2 | 2020 | 253 | 0.270 |
Why?
|
Isoniazid | 2 | 2017 | 274 | 0.250 |
Why?
|
Primary Health Care | 1 | 2021 | 4558 | 0.250 |
Why?
|
HIV Infections | 6 | 2022 | 16718 | 0.250 |
Why?
|
Humans | 50 | 2022 | 744343 | 0.240 |
Why?
|
World Health Organization | 3 | 2020 | 1318 | 0.230 |
Why?
|
Molecular Diagnostic Techniques | 2 | 2019 | 602 | 0.230 |
Why?
|
Physicians | 1 | 2021 | 4567 | 0.220 |
Why?
|
Disease Transmission, Infectious | 2 | 2020 | 547 | 0.220 |
Why?
|
Practice Guidelines as Topic | 1 | 2019 | 7279 | 0.210 |
Why?
|
Air Conditioning | 1 | 2020 | 50 | 0.180 |
Why?
|
Artificial Intelligence | 3 | 2022 | 2214 | 0.180 |
Why?
|
Technology | 1 | 2021 | 305 | 0.170 |
Why?
|
Peru | 2 | 2021 | 881 | 0.160 |
Why?
|
Public Sector | 2 | 2016 | 265 | 0.160 |
Why?
|
Carbon Dioxide | 1 | 2022 | 1150 | 0.160 |
Why?
|
Aerosols | 1 | 2020 | 625 | 0.150 |
Why?
|
Human Rights | 2 | 2017 | 307 | 0.150 |
Why?
|
Laboratory Personnel | 1 | 2017 | 19 | 0.150 |
Why?
|
Infectious Disease Transmission, Professional-to-Patient | 1 | 2017 | 35 | 0.150 |
Why?
|
Ethambutol | 1 | 2017 | 60 | 0.150 |
Why?
|
Mycobacterium avium-intracellulare Infection | 1 | 2017 | 76 | 0.150 |
Why?
|
National Health Programs | 1 | 2020 | 445 | 0.140 |
Why?
|
Tuberculosis, Osteoarticular | 1 | 2016 | 26 | 0.140 |
Why?
|
Antigens, Bacterial | 1 | 2022 | 1171 | 0.140 |
Why?
|
Food Parasitology | 1 | 2015 | 6 | 0.130 |
Why?
|
Occupational Health Services | 1 | 2017 | 154 | 0.130 |
Why?
|
DNA Probes | 1 | 2017 | 560 | 0.130 |
Why?
|
Reference Standards | 1 | 2019 | 1025 | 0.130 |
Why?
|
Praziquantel | 1 | 2015 | 25 | 0.130 |
Why?
|
Anura | 1 | 2015 | 86 | 0.130 |
Why?
|
Disease Susceptibility | 1 | 2022 | 1782 | 0.130 |
Why?
|
Bangladesh | 1 | 2017 | 687 | 0.130 |
Why?
|
Africa, Western | 1 | 2015 | 154 | 0.130 |
Why?
|
Foodborne Diseases | 1 | 2015 | 39 | 0.130 |
Why?
|
Antiparasitic Agents | 1 | 2015 | 41 | 0.130 |
Why?
|
Immunity, Cellular | 1 | 2021 | 1607 | 0.130 |
Why?
|
Ethiodized Oil | 1 | 2014 | 33 | 0.120 |
Why?
|
Transients and Migrants | 1 | 2017 | 155 | 0.120 |
Why?
|
Ultraviolet Rays | 1 | 2019 | 1060 | 0.120 |
Why?
|
Climate Change | 1 | 2020 | 418 | 0.120 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2019 | 719 | 0.120 |
Why?
|
Early Diagnosis | 1 | 2019 | 1184 | 0.120 |
Why?
|
Food Contamination | 1 | 2015 | 188 | 0.120 |
Why?
|
Counseling | 1 | 2022 | 1523 | 0.120 |
Why?
|
Lipopolysaccharides | 1 | 2021 | 2216 | 0.120 |
Why?
|
Emigration and Immigration | 1 | 2016 | 404 | 0.110 |
Why?
|
Radiography, Abdominal | 1 | 2017 | 537 | 0.110 |
Why?
|
Optic Nerve Diseases | 1 | 2017 | 327 | 0.110 |
Why?
|
Chemoembolization, Therapeutic | 1 | 2014 | 129 | 0.110 |
Why?
|
Radiography, Thoracic | 1 | 2019 | 1265 | 0.110 |
Why?
|
Knee Prosthesis | 1 | 2016 | 425 | 0.110 |
Why?
|
Quality of Health Care | 2 | 2019 | 4371 | 0.110 |
Why?
|
Bronchoalveolar Lavage Fluid | 1 | 2014 | 768 | 0.100 |
Why?
|
Health Services Needs and Demand | 2 | 2017 | 1411 | 0.100 |
Why?
|
India | 2 | 2016 | 2197 | 0.100 |
Why?
|
North America | 1 | 2015 | 1249 | 0.100 |
Why?
|
Antibodies, Neutralizing | 1 | 2021 | 1978 | 0.100 |
Why?
|
Retinal Ganglion Cells | 1 | 2017 | 770 | 0.100 |
Why?
|
Delivery of Health Care | 2 | 2022 | 5319 | 0.100 |
Why?
|
Drainage | 1 | 2017 | 1142 | 0.100 |
Why?
|
Prevalence | 2 | 2017 | 15226 | 0.090 |
Why?
|
Conization | 1 | 2010 | 14 | 0.090 |
Why?
|
Health Services Accessibility | 3 | 2017 | 5137 | 0.090 |
Why?
|
Safety Management | 1 | 2016 | 783 | 0.090 |
Why?
|
Program Evaluation | 1 | 2019 | 2488 | 0.090 |
Why?
|
Prosthesis-Related Infections | 1 | 2016 | 538 | 0.090 |
Why?
|
Antibodies, Viral | 1 | 2021 | 3176 | 0.090 |
Why?
|
Patient-Centered Care | 2 | 2017 | 1439 | 0.090 |
Why?
|
Neoplasms, Squamous Cell | 1 | 2010 | 96 | 0.090 |
Why?
|
Radiography, Interventional | 1 | 2017 | 1095 | 0.090 |
Why?
|
China | 1 | 2015 | 2248 | 0.080 |
Why?
|
History, 21st Century | 1 | 2015 | 1534 | 0.080 |
Why?
|
Social Stigma | 1 | 2015 | 701 | 0.080 |
Why?
|
Referral and Consultation | 1 | 2022 | 3528 | 0.080 |
Why?
|
Cross-Sectional Studies | 3 | 2020 | 25043 | 0.080 |
Why?
|
Emergencies | 1 | 2015 | 1170 | 0.080 |
Why?
|
Middle Aged | 9 | 2021 | 213383 | 0.080 |
Why?
|
Adult | 8 | 2021 | 214055 | 0.080 |
Why?
|
Polymerase Chain Reaction | 1 | 2018 | 6171 | 0.080 |
Why?
|
Solar System | 1 | 2007 | 12 | 0.080 |
Why?
|
Bacterial Infections | 1 | 2017 | 1401 | 0.080 |
Why?
|
Risk Factors | 3 | 2021 | 72290 | 0.080 |
Why?
|
Anti-Infective Agents | 1 | 2015 | 972 | 0.070 |
Why?
|
Mycobacterium bovis | 1 | 2007 | 150 | 0.070 |
Why?
|
Occupational Exposure | 1 | 2017 | 1796 | 0.070 |
Why?
|
Incidence | 2 | 2022 | 20947 | 0.070 |
Why?
|
Young Adult | 4 | 2021 | 56430 | 0.070 |
Why?
|
Equipment Contamination | 1 | 2007 | 185 | 0.070 |
Why?
|
Cohort Studies | 2 | 2019 | 40561 | 0.070 |
Why?
|
Risk | 1 | 2017 | 9687 | 0.060 |
Why?
|
SEER Program | 1 | 2010 | 1508 | 0.060 |
Why?
|
Child | 4 | 2019 | 77709 | 0.060 |
Why?
|
Hysterectomy | 1 | 2010 | 927 | 0.060 |
Why?
|
Students, Medical | 1 | 2017 | 1862 | 0.060 |
Why?
|
Research Design | 1 | 2019 | 5987 | 0.060 |
Why?
|
Private Sector | 2 | 2016 | 392 | 0.060 |
Why?
|
Specimen Handling | 1 | 2007 | 694 | 0.050 |
Why?
|
Female | 8 | 2021 | 380194 | 0.050 |
Why?
|
Genetic Variation | 1 | 2017 | 6544 | 0.050 |
Why?
|
Child, Preschool | 3 | 2019 | 41006 | 0.050 |
Why?
|
Quality Improvement | 1 | 2016 | 3749 | 0.050 |
Why?
|
Pulmonary Embolism | 1 | 2014 | 2376 | 0.050 |
Why?
|
X-Rays | 1 | 2022 | 301 | 0.050 |
Why?
|
Male | 7 | 2021 | 350118 | 0.050 |
Why?
|
Arthritis, Rheumatoid | 1 | 2016 | 3712 | 0.050 |
Why?
|
Prospective Studies | 2 | 2021 | 53288 | 0.050 |
Why?
|
Health Policy | 3 | 2017 | 2661 | 0.040 |
Why?
|
Reagent Kits, Diagnostic | 1 | 2021 | 224 | 0.040 |
Why?
|
Europe | 2 | 2017 | 3339 | 0.040 |
Why?
|
Equipment Design | 1 | 2007 | 3582 | 0.040 |
Why?
|
Anti-Bacterial Agents | 1 | 2017 | 7181 | 0.040 |
Why?
|
Hospitalization | 1 | 2017 | 10262 | 0.040 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2010 | 2020 | 0.040 |
Why?
|
Quality Assurance, Health Care | 2 | 2019 | 2212 | 0.040 |
Why?
|
Mycobacterium avium Complex | 1 | 2017 | 60 | 0.040 |
Why?
|
Hospitals, General | 1 | 2021 | 749 | 0.040 |
Why?
|
Nitroimidazoles | 1 | 2017 | 106 | 0.040 |
Why?
|
False Negative Reactions | 1 | 2018 | 588 | 0.040 |
Why?
|
Immunity, Humoral | 1 | 2021 | 598 | 0.040 |
Why?
|
Software | 2 | 2022 | 4443 | 0.040 |
Why?
|
Oxazoles | 1 | 2017 | 189 | 0.030 |
Why?
|
Policy | 1 | 2020 | 508 | 0.030 |
Why?
|
Confidence Intervals | 1 | 2021 | 2971 | 0.030 |
Why?
|
Retreatment | 1 | 2017 | 610 | 0.030 |
Why?
|
Area Under Curve | 1 | 2019 | 1654 | 0.030 |
Why?
|
Retrospective Studies | 2 | 2021 | 77449 | 0.030 |
Why?
|
Adolescent | 3 | 2017 | 85781 | 0.030 |
Why?
|
Injections | 1 | 2017 | 840 | 0.030 |
Why?
|
Stem Cells | 1 | 2007 | 3567 | 0.030 |
Why?
|
Epidemics | 1 | 2020 | 523 | 0.030 |
Why?
|
Patient Care | 1 | 2020 | 640 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2017 | 20129 | 0.030 |
Why?
|
Microscopy | 1 | 2016 | 903 | 0.020 |
Why?
|
Diagnostic Errors | 1 | 2018 | 1257 | 0.020 |
Why?
|
Program Development | 1 | 2016 | 1316 | 0.020 |
Why?
|
Refugees | 1 | 2017 | 511 | 0.020 |
Why?
|
Communicable Disease Control | 1 | 2016 | 857 | 0.020 |
Why?
|
Fatal Outcome | 1 | 2014 | 1850 | 0.020 |
Why?
|
Influenza, Human | 1 | 2020 | 1479 | 0.020 |
Why?
|
Odds Ratio | 1 | 2021 | 9849 | 0.020 |
Why?
|
Radiography | 1 | 2019 | 7023 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2021 | 12026 | 0.020 |
Why?
|
Infant, Newborn | 2 | 2016 | 25625 | 0.020 |
Why?
|
Time Factors | 1 | 2007 | 40075 | 0.020 |
Why?
|
Medication Adherence | 1 | 2016 | 2063 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2017 | 10943 | 0.020 |
Why?
|
Infant | 2 | 2016 | 35136 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2021 | 9959 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2016 | 3589 | 0.020 |
Why?
|
Infertility, Female | 1 | 2010 | 787 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2019 | 15076 | 0.010 |
Why?
|
Animals | 1 | 2015 | 168757 | 0.010 |
Why?
|
Health Care Costs | 1 | 2016 | 3209 | 0.010 |
Why?
|
Aged, 80 and over | 2 | 2018 | 57776 | 0.010 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2014 | 2214 | 0.010 |
Why?
|
Neoplasm Invasiveness | 1 | 2010 | 3616 | 0.010 |
Why?
|
Mass Screening | 1 | 2017 | 5255 | 0.010 |
Why?
|
Age Factors | 1 | 2016 | 18370 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2010 | 6538 | 0.010 |
Why?
|
Liver Neoplasms | 1 | 2014 | 4253 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2010 | 12354 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2010 | 11031 | 0.010 |
Why?
|
Treatment Outcome | 1 | 2017 | 63114 | 0.010 |
Why?
|
Aged | 1 | 2018 | 163280 | 0.000 |
Why?
|